Insider · CIK 0001376043
Timothy Coughlin
director
Files at ATYR (aTYR PHARMA INC), TVTX (Travere Therapeutics, Inc.), ADCT (ADC Therapeutics SA). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | ADCT ADC Therapeutics SA | AGrant or award Common Shares | +40,000 | $0.00 | $0 | 40,000 | Jun 5, 2025 |
| Jun 3, 2025 | ADCT ADC Therapeutics SA | AGrant or award Stock Options (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 5, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 55,500 | May 16, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | May 16, 2025 |
| May 1, 2025 | ATYR aTYR PHARMA INC | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.